<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6270">
  <stage>Registered</stage>
  <submitdate>17/10/2016</submitdate>
  <approvaldate>17/10/2016</approvaldate>
  <nctid>NCT02937272</nctid>
  <trial_identification>
    <studytitle>A Study of LY3200882 in Participants With Solid Tumors</studytitle>
    <scientifictitle>A Phase 1 Study of LY3200882 in Patients With Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I8X-MC-JECA</secondaryid>
    <secondaryid>16185</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Solid Tumor</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY3200882
Treatment: drugs - LY3300054
Treatment: drugs - Gemcitabine
Treatment: drugs - nab-Paclitaxel
Treatment: drugs - Cisplatin
Treatment: other - Intensity Modulated Radiotherapy

Experimental: LY3200882 Schedule 1 Escalation - 

Experimental: LY3200882 Schedule 2 Escalation - 

Experimental: LY3200882 Schedule 1 Expansion - 

Experimental: LY3200882 Schedule 2 Expansion - 

Experimental: LY3200882 + LY3300054 - 

Experimental: LY3200882 + Gemcitabine + nab-Paclitaxel - 

Experimental: LY3200882 + Cisplatin + Radiation - 


Treatment: drugs: LY3200882
Administered orally

Treatment: drugs: LY3300054
Administered intravenously

Treatment: drugs: Gemcitabine
Administered intravenously

Treatment: drugs: nab-Paclitaxel
Administered intravenously

Treatment: drugs: Cisplatin
Administered intravenously

Treatment: other: Intensity Modulated Radiotherapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</outcome>
      <timepoint>Cycle 1 (28 days)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)</outcome>
      <timepoint>Baseline through Disease Progression or Death (estimated at up to 12 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Area Under the Curve (AUC) (AUC[0-24]) at Steady State of LY3200882</outcome>
      <timepoint>Cycle 1 Day 1 through Cycle 2 Day 14 (28 day cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: AUC Zero to Infinity (AUC[0-8]) at Steady State of LY3200882</outcome>
      <timepoint>Cycle 1 Day 1 through Cycle 2 Day 14 (28 day cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ORR: Percentage of Participants with CR or PR</outcome>
      <timepoint>Baseline through Disease Progression or Death (estimated at up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Baseline to Date of Death from Any Cause (estimated at up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DoR)</outcome>
      <timepoint>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (estimated at up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-Free Survival (PFS)</outcome>
      <timepoint>Baseline to Disease Progression or Death (estimated at up to 12 months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The participant must have histological or cytological evidence of cancer.

          -  Have adequate organ function.

          -  Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.

          -  Are able to swallow capsules and tablets.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have moderate or severe cardiovascular disease.

          -  Have a serious concomitant systemic disorder.

          -  Have acute leukemia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>21/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>149</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Greenslopes</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Newcastle</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Sydney</hospital>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Ticino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to evaluate the safety of the study drug known as LY3200882
      in participants with solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02937272</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</name>
      <address />
      <phone>1-317-615-4559</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>